术前锥切与早期宫颈癌腹腔镜根治性子宫切除术后复发风险:多中心研究
该多中心回顾性研究纳入186例2009 FIGO IA(淋巴血管间隙浸润阳性)-IB1期宫颈癌患者,均行腹腔镜根治性子宫切除术。中位随访37.9个月,16例(8.6%)复发,9例(4.8%)死于疾病。术前经锥切诊断者复发率显著低于宫颈活检者(1.1% vs 16.1%,p<.001),IB1期亚组锥切者复发风险更低(OR 0.09,95%CI 0.01-0.55)。
要点
- 术前锥切诊断与IB1期宫颈癌腹腔镜根治术后更低复发率相关。
- 肿瘤大小≥2 cm是影响无病生存的最重要危险因素。
- 淋巴结阳性与复发无显著关联(p=.82)。
核心结论
- 腹腔镜根治性子宫切除术的复发率与LACC试验报道相似。
- 肿瘤大小≥2 cm是影响无病生存的最重要危险因素。
- 术前锥切对IB1期肿瘤患者可能具有保护作用。
研究设计与样本
- 多中心回顾性研究,纳入三个妇科肿瘤转诊中心2006年1月至2018年6月间186例2009 FIGO IA(淋巴血管间隙浸润阳性)-IB1期宫颈癌患者。
- 所有患者行腹腔镜根治性子宫切除术(Piver II-III型),并根据肿瘤特征行淋巴结清扫。
主要发现
- 中位随访37.9个月,16例(8.6%)复发,9例(4.8%)死于疾病。
- 所有复发(16/16,100%)均发生于IB1期患者(p=.02),其中15例(93.7%)肿瘤≥2 cm。
- 淋巴结阳性与复发无关联(p=.82)。
- 术前锥切诊断者复发率显著低于宫颈活检者:1/93(1.1%)vs 15/93(16.1%),p<.001。
- IB1期亚组中,术前锥切者复发风险更低(OR 0.09,95%CI 0.01-0.55)。
临床怎么用
- 对于早期宫颈癌拟行腹腔镜根治性子宫切除术的患者,术前锥切诊断可能有助于降低复发风险。
- 肿瘤大小≥2 cm应视为影响无病生存的重要高危因素,需加强术后监测。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本量有限,亚组分析结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To investigate the factors associated with poorer oncologic outcomes in patients undergoing laparoscopic radical hysterectomy (LRH) for early stage cervical cancer. DESIGN: Multicenter retrospective study. SETTING: Three gynecologic oncology referral centers. PATIENTS: Patients with International Federation of Gynecology and Obstetrics 2009 stage IA (positive lymphovascular space invasion)-IB1 cervical cancer between January 2006 and June 2018. INTERVENTIONS: LRH (Piver type II-III hysterectomies). Lymph-node dissection was accomplished according to the tumor characteristics. MEASUREMENTS AND MAIN RESULTS: Surgical and oncologic outcomes were analyzed. Overall, 186 patients met the inclusion criteria, 16 (8.6%) experienced a recurrence, and 9 (4.8%) died of the disease (median follow-up period 37.9 months). Surgery-related complications did not influence disease-free survival. All the recurrences (16/16; 100%) occurred in patients with stage IB1 disease (p = .02), and 15 (93.7%) in cases involving tumors ≥2 cm. No association between positive lymph node and recurrence was detected (p =.82). Patients who had a preoperative diagnosis through conization (93; 50%) had a significantly lower rate of recurrence than those who underwent cervical biopsy (93; 50%): 1/93 (1.1%) vs 15/93 (16.1%); p <.001). The subanalysis of patients with International Federation of Gynecology and Obstetrics stage IB1 cervical cancer showed that patients undergoing preoperative conization (vs cervical biopsy) were less likely to experience a recurrence (odds ratio 0.09; 95% confidence interval 0.01-0.55). CONCLUSION: We confirmed that LRH was associated with a recurrence rate similar to that reported in the Laparoscopic Approach to Cervical Cancer trial. Tumor size ≥2 cm represents the most important risk factor influencing disease-free survival. However, we found that preoperative conization plays a potentially protective role in patients with an IB1 tumor.
引用
- Casarin J, Bogani G, Papadia A, et al. Preoperative Conization and Risk of Recurrence in Patients Undergoing Laparoscopic Radical Hysterectomy for Early Stage Cervical Cancer: A Multicenter Study. J Minim Invasive Gynecol. 2020. PMID: 32320800. doi:10.1016/j.jmig.2020.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。